Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
Phase 1 Withdrawn
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Phase 1 Withdrawn
Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation
Phase 1 Withdrawn
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Phase 1 Withdrawn
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
Phase 1 Withdrawn
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Phase 1 Withdrawn
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
Phase 1 Withdrawn
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
Phase 1 Withdrawn
StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord
Phase 1 Withdrawn
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
Phase 1 Withdrawn
A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas
Phase 1 Withdrawn
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
Phase 1 Withdrawn
GLIOASTRA
Phase 1 Withdrawn
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Phase 1 Withdrawn
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
Phase 1 Withdrawn
RiNG
Phase 1 Withdrawn
DEMAND
Phase 1 Withdrawn
Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2
Phase 1 Withdrawn
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
Phase 1 Withdrawn
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Phase 1 Withdrawn
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Phase 1 Withdrawn
Scalp block
Phase 1 Withdrawn
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Phase 1 Withdrawn
Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
Phase 1 Withdrawn
Study of Busulfan for Refractory Central Nervous System (CNS) Tumors
Phase 1 Withdrawn
PARADIGMA
Phase 1 Withdrawn
HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
Phase 1 Withdrawn
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Phase 1 Withdrawn
A Vaccine Study for High Risk Cancers
Phase 1 Withdrawn
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma
Phase 1 Withdrawn
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
Phase 1 Withdrawn
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Phase 1 Withdrawn
GINAKIT
Phase 1 Withdrawn
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Withdrawn
OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas
Phase 1 Withdrawn
Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma
Phase 1 Withdrawn
Valproic Acid in Childhood Progressive Brain Tumors
Phase 1 Withdrawn
Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme
Phase 1 Withdrawn
Safety Study of 2DG With Stereotactic Radiosurgery
Phase 1 Withdrawn
18-F-Fluoroacetate as PET Imaging Agent
Phase 1 Withdrawn
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Phase 1 Withdrawn
Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
Phase 1 Withdrawn
Phase I Dose Escalation in Patients With 1-3 Unresectable Brain Metastases
Phase 1 Withdrawn
PERFORMANCE
Phase 1 Withdrawn
Aflac ST1001
Phase 1 Withdrawn
Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis
Phase 1 Withdrawn
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
Phase 1 Withdrawn
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
Phase 1 Withdrawn
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
Phase 1 Withdrawn
SCH-900105 in Recurrent Glioblastoma
Phase 1 Withdrawn